Prihlásiť sa Zaregistrujte sa zadarmo

Výnosy spoločnosti SinoMab BioScience

Aká je hodnota metriky Výnosy spoločnosti SinoMab BioScience?

Hodnota metriky Výnosy spoločnosti SinoMab BioScience Limited je -¥2.06

Aká je definícia metriky Výnosy?



Výnosy (Revenue) je príjem, ktorý má podnik zo svojich činností, typicky z predaja tovaru a služieb zákazníkom.

Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.

In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.

Výnosy spoločností v sektore Health Care sektor na HKSE v porovnaní so spoločnosťou SinoMab BioScience

Čomu sa venuje spoločnosť SinoMab BioScience?

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Firmy s metrikou výnosy podobnou spoločnosti SinoMab BioScience